Please assess the completion status of the following clinical trial:

Trial Title: A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with a non-myeloid malignancy~* Anemia~Exclusion Criteria:~* Transfusion of red blood cells within 2 months of study drug~* Treatment-resistant hypertension~* Acute or chronic bleeding (requiring therapy) within 3 months of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epoetin Beta 30000 IU (Type: EXPERIMENTAL): Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).